	US 11,986,534 B1
	Treatment of anthrax with pegylated capsule-degrading enzyme
Patricia M. Legler, Derwood, MD (US); Arthur M. Friedlander, Frederick, MD (US); and Jaimee R. Compton, Washington, DC (US)
Assigned to The Government of the United States of America, as represented by the Secretary of the Navy, Arlington, VA (US)
Filed by The Government of the United States of America, as represented by the Secretary of the Navy, Arlington, VA (US)
Filed on Sep. 22, 2023, as Appl. No. 18/472,953.
Application 18/472,953 is a division of application No. 17/577,893, filed on Jan. 18, 2022, granted, now 11,786,601.
Claims priority of provisional application 63/140,455, filed on Jan. 22, 2021.
Int. Cl. A61K 47/60 (2017.01); A61K 38/45 (2006.01)

CPC A61K 47/60 (2017.08) [A61K 38/45 (2013.01)]

5 Claims

1. A method of treating an infection of bacteria in a subject in need thereof, the method comprising:

administering a pegylated protein comprising SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, or SEQ ID NO: 5 to the subject,

wherein the bacteria has a capsule and is Bacillus anthracis or Staphylococcus epidermidis.